|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UTP4 |
Gene summary for UTP4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UTP4 | Gene ID | 84916 |
| Gene name | UTP4 small subunit processome component | |
| Gene Alias | CIRH1A | |
| Cytomap | 16q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000462 | UniProtAcc | Q969X6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84916 | UTP4 | LZE4T | Human | Esophagus | ESCC | 1.28e-08 | 2.73e-01 | 0.0811 |
| 84916 | UTP4 | LZE8T | Human | Esophagus | ESCC | 4.08e-04 | 1.49e-01 | 0.067 |
| 84916 | UTP4 | LZE24T | Human | Esophagus | ESCC | 6.72e-08 | 3.17e-01 | 0.0596 |
| 84916 | UTP4 | LZE21T | Human | Esophagus | ESCC | 2.86e-02 | 5.94e-02 | 0.0655 |
| 84916 | UTP4 | P1T-E | Human | Esophagus | ESCC | 2.44e-04 | 9.57e-02 | 0.0875 |
| 84916 | UTP4 | P2T-E | Human | Esophagus | ESCC | 6.59e-11 | 1.00e-01 | 0.1177 |
| 84916 | UTP4 | P4T-E | Human | Esophagus | ESCC | 2.42e-14 | 5.01e-01 | 0.1323 |
| 84916 | UTP4 | P5T-E | Human | Esophagus | ESCC | 1.45e-10 | 3.13e-01 | 0.1327 |
| 84916 | UTP4 | P8T-E | Human | Esophagus | ESCC | 9.70e-18 | 2.45e-01 | 0.0889 |
| 84916 | UTP4 | P9T-E | Human | Esophagus | ESCC | 2.50e-10 | 1.27e-01 | 0.1131 |
| 84916 | UTP4 | P10T-E | Human | Esophagus | ESCC | 4.90e-13 | 1.48e-01 | 0.116 |
| 84916 | UTP4 | P11T-E | Human | Esophagus | ESCC | 9.66e-12 | 3.21e-01 | 0.1426 |
| 84916 | UTP4 | P12T-E | Human | Esophagus | ESCC | 1.58e-09 | 2.25e-01 | 0.1122 |
| 84916 | UTP4 | P15T-E | Human | Esophagus | ESCC | 1.33e-23 | 2.63e-01 | 0.1149 |
| 84916 | UTP4 | P16T-E | Human | Esophagus | ESCC | 1.51e-08 | 1.56e-01 | 0.1153 |
| 84916 | UTP4 | P17T-E | Human | Esophagus | ESCC | 1.85e-06 | 3.55e-01 | 0.1278 |
| 84916 | UTP4 | P19T-E | Human | Esophagus | ESCC | 2.67e-04 | 4.31e-01 | 0.1662 |
| 84916 | UTP4 | P20T-E | Human | Esophagus | ESCC | 2.29e-14 | 4.31e-01 | 0.1124 |
| 84916 | UTP4 | P21T-E | Human | Esophagus | ESCC | 4.46e-25 | 5.89e-01 | 0.1617 |
| 84916 | UTP4 | P22T-E | Human | Esophagus | ESCC | 8.11e-10 | 2.20e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0042274111 | Esophagus | ESCC | ribosomal small subunit biogenesis | 67/8552 | 73/18723 | 6.62e-17 | 5.38e-15 | 67 |
| GO:00304904 | Esophagus | ESCC | maturation of SSU-rRNA | 45/8552 | 50/18723 | 5.07e-11 | 1.63e-09 | 45 |
| GO:00004623 | Esophagus | ESCC | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 32/8552 | 37/18723 | 2.96e-07 | 4.23e-06 | 32 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:001607212 | Liver | HCC | rRNA metabolic process | 193/7958 | 236/18723 | 1.26e-35 | 1.14e-32 | 193 |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004227422 | Liver | HCC | ribosomal small subunit biogenesis | 65/7958 | 73/18723 | 1.09e-16 | 9.92e-15 | 65 |
| GO:00304901 | Liver | HCC | maturation of SSU-rRNA | 43/7958 | 50/18723 | 2.35e-10 | 8.04e-09 | 43 |
| GO:00004621 | Liver | HCC | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 30/7958 | 37/18723 | 1.78e-06 | 2.48e-05 | 30 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UTP4 | SNV | Missense_Mutation | c.934N>T | p.Arg312Cys | p.R312C | Q969X6 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-BH-A0HL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| UTP4 | SNV | Missense_Mutation | c.1413N>G | p.Phe471Leu | p.F471L | Q969X6 | protein_coding | tolerated(0.74) | benign(0) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| UTP4 | SNV | Missense_Mutation | c.1970N>C | p.Asp657Ala | p.D657A | Q969X6 | protein_coding | deleterious(0.01) | benign(0.386) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| UTP4 | insertion | In_Frame_Ins | novel | c.1886_1894dupAATCAGATG | p.Glu629_Asp631dup | p.E629_D631dup | Q969X6 | protein_coding | TCGA-A2-A1G1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| UTP4 | insertion | Frame_Shift_Ins | novel | c.658_659insCCCTCTTTGAAGCCCCACTTACTCCTTTTCTAGAATA | p.Phe220SerfsTer29 | p.F220Sfs*29 | Q969X6 | protein_coding | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| UTP4 | insertion | Frame_Shift_Ins | novel | c.652_653insACCTGGATATGTCTGTCCGAGGAATATCCTTTGAAATAGTTAC | p.Val218AspfsTer33 | p.V218Dfs*33 | Q969X6 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| UTP4 | insertion | In_Frame_Ins | novel | c.824_825insACAAAAAAAGATGAGGTCTCACTATGTTGT | p.Gln276_Trp277insLysLysMetArgSerHisTyrValValGln | p.Q276_W277insKKMRSHYVVQ | Q969X6 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| UTP4 | SNV | Missense_Mutation | novel | c.769N>A | p.Glu257Lys | p.E257K | Q969X6 | protein_coding | deleterious(0.02) | benign(0.251) | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| UTP4 | SNV | Missense_Mutation | novel | c.592N>A | p.Val198Met | p.V198M | Q969X6 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-AA-3692-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | PD |
| UTP4 | SNV | Missense_Mutation | c.1158G>T | p.Lys386Asn | p.K386N | Q969X6 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |